Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Bioactivation of drugs: risk and drug design.

Walsh JS, Miwa GT.

Annu Rev Pharmacol Toxicol. 2011;51:145-67. doi: 10.1146/annurev-pharmtox-010510-100514. Review.

PMID:
21210745
2.

Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.

Tengstrand EA, Miwa GT, Hsieh FY.

Expert Opin Drug Metab Toxicol. 2010 May;6(5):555-70. doi: 10.1517/17425251003601961. Review.

PMID:
20370598
3.

Interactions of cyclosporin a with breast cancer resistance protein.

Xia CQ, Liu N, Miwa GT, Gan LS.

Drug Metab Dispos. 2007 Apr;35(4):576-82. Epub 2007 Jan 12.

4.

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.

Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.

Drug Metab Dispos. 2007 Jan;35(1):79-85. Epub 2006 Oct 4.

5.

Determination of drug plasma protein binding by solid phase microextraction.

Musteata FM, Pawliszyn J, Qian MG, Wu JT, Miwa GT.

J Pharm Sci. 2006 Aug;95(8):1712-22.

PMID:
16795010
6.

Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes.

Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS.

Drug Metab Dispos. 2006 Sep;34(9):1600-5. Epub 2006 Jun 21.

7.

Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.

Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS.

Drug Metab Dispos. 2006 Apr;34(4):702-8. Epub 2006 Jan 27.

8.

Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.

Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT.

Drug Metab Dispos. 2006 Mar;34(3):384-8. Epub 2005 Dec 2.

9.

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.

Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW.

Curr Top Med Chem. 2005;5(11):1033-8. Review.

PMID:
16181128
10.

Testing paradigm for prediction of development-limiting barriers and human drug toxicity.

Sasseville VG, Lane JH, Kadambi VJ, Bouchard P, Lee FW, Balani SK, Miwa GT, Smith PF, Alden CL.

Chem Biol Interact. 2004 Nov 1;150(1):9-25. Review.

PMID:
15522258
11.

The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats.

Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT.

Toxicol Appl Pharmacol. 2000 Nov 15;169(1):102-13.

PMID:
11076702
12.

The life and times of anthony Y. H. Lu

Miwa GT.

Drug Metab Dispos. 1998 Dec;26(12):1174. No abstract available.

13.

Goals, design, timing, and future opportunities for nonclinical drug metabolism studies.

Miwa GT.

Toxicol Pathol. 1995 Mar-Apr;23(2):131-5. Review.

PMID:
7569666
14.
15.

(-)-6-Aminocarbovir pharmacokinetics and relative carbovir exposure in rats.

Yeager RL, Brouwer KR, Miwa GT.

Drug Metab Dispos. 1991 Mar-Apr;19(2):462-6.

PMID:
1676655
16.

Identification of a glucuronide conjugate of the carbocyclic nucleoside, carbovir, isolated from marmoset urine.

Patanella JE, Walsh JS, Unger SE, Miwa GT, Parry PS, Daniel MJ, Evans GL.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1092-5. No abstract available.

PMID:
1981518
17.

The metabolism and excretion of carbovir, a carbocyclic nucleoside, in the rat.

Walsh JS, Patanella JE, Unger SE, Brouwer KR, Miwa GT.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1084-91.

PMID:
1981517
18.

The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination.

Brouwer KR, St Claire RL, Lagarde J, Patanella JE, Walsh JS, Miwa GT.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1078-83.

PMID:
1981516
19.

The role of metabolism and covalent binding in the cytotoxicity of a nitrogen-containing steroid toward rat hepatocytes.

Kedderis GL, Argenbright LS, Miwa GT.

Toxicol Appl Pharmacol. 1990 Apr;103(2):222-7.

PMID:
2330586
20.

Metabolism of a nitrogen-containing steroid by rat hepatocytes and hepatic subcellular fractions.

Kedderis GL, Argenbright LS, Walsh JS, Smith JL, Stearns RA, Arison BA, Miwa GT.

Drug Metab Dispos. 1989 Nov-Dec;17(6):606-11.

PMID:
2575495
21.

Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: mechanism of reductive activation.

Kedderis GL, Argenbright LS, Miwa GT.

Chem Res Toxicol. 1989 May-Jun;2(3):146-9.

PMID:
2519718
22.

In vitro studies on the interaction of famotidine with liver microsomal cytochrome P-450.

Wang RW, Miwa GT, Argenbright LS, Lu AY.

Biochem Pharmacol. 1988 Aug 1;37(15):3049-53. No abstract available.

PMID:
2899433
23.

Studies with nitrogen-containing steroids and freshly isolated rat hepatocytes: role of cytochrome P-450 in detoxication.

Kedderis GL, Argenbright LS, Miwa GT.

Toxicol Appl Pharmacol. 1988 May;93(3):403-12.

PMID:
3368919
24.

Mechanism of reductive activation of a 5-nitroimidazole by flavoproteins: model studies with dithionite.

Kedderis GL, Argenbright LS, Miwa GT.

Arch Biochem Biophys. 1988 Apr;262(1):40-8.

PMID:
3128179
25.

The metabolic activation of nitroheterocyclic therapeutic agents.

Kedderis GL, Miwa GT.

Drug Metab Rev. 1988;19(1):33-62. Review. No abstract available.

PMID:
3293954
26.

Kinetic isotope effects and 'metabolic switching' in cytochrome P450-catalyzed reactions.

Miwa GT, Lu AY.

Bioessays. 1987 Nov;7(5):215-9. Review. No abstract available.

PMID:
3325050
27.

Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles.

Walsh JS, Wang R, Bagan E, Wang CC, Wislocki P, Miwa GT.

J Med Chem. 1987 Jan;30(1):150-6.

PMID:
3543363
28.

Tissue drug residues and their toxicological significance.

Lu AY, Wislocki PG, Chiu SH, Miwa GT.

Drug Metab Rev. 1987;18(2-3):363-78. Review. No abstract available.

PMID:
3330522
29.

The metabolic activation of ronidazole [(1-methyl-5-nitroimidazole-2-yl)-methyl carbamate] to reactive metabolites by mammalian, cecal bacterial and T. foetus enzymes.

Miwa GT, Wang R, Alvaro R, Walsh JS, Lu AY.

Biochem Pharmacol. 1986 Jan 1;35(1):33-6. No abstract available.

PMID:
3940524
30.

Studies on the mechanism of activation and the mutagenicity of ronidazole, a 5-nitroimidazole.

Miwa GT, Wislocki P, Bagan E, Wang R, Walsh JS, Lu AY.

Adv Exp Med Biol. 1986;197:527-35.

PMID:
3766278
31.

Role of superoxide in the N-oxidation of N-(2-methyl-1-phenyl-2-propyl)hydroxylamine by the rat liver cytochrome P-450 system.

Duncan JD, Di Stefano EW, Miwa GT, Cho AK.

Biochemistry. 1985 Jul 16;24(15):4155-61.

PMID:
2996591
33.

Mechanisms of N-demethylation reactions catalyzed by cytochrome P-450 and peroxidases.

Hollenberg PF, Miwa GT, Walsh JS, Dwyer LA, Rickert DE, Kedderis GL.

Drug Metab Dispos. 1985 May-Jun;13(3):272-5. No abstract available.

PMID:
2861981
34.
35.

Drug residue formation from ronidazole, a 5-nitroimidazole. VII. Comparison of protein-bound products formed in vitro and in vivo.

Miwa GT, Alvaro RF, Walsh JS, Wang R, Lu AY.

Chem Biol Interact. 1984 Jul;50(2):189-202.

PMID:
6744464
36.

The mechanism of the cytochrome P-448 mediated 6-hydroxylation of 7-ethoxycoumarin.

Walsh JS, Miwa GT.

Biochem Biophys Res Commun. 1984 Jun 29;121(3):960-5.

PMID:
6611155
39.

N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen.

Dahlin DC, Miwa GT, Lu AY, Nelson SD.

Proc Natl Acad Sci U S A. 1984 Mar;81(5):1327-31.

40.

Mechanism of metabolic activation of ronidazole, a 5-nitroimidazole.

Lu AY, Wislocki PG, Bagan ES, Wang RW, Walsh JS, Miwa GT.

Biochem Soc Trans. 1984 Feb;12(1):7-9. No abstract available.

PMID:
6705992
41.
43.

Drug residue formation from ronidazole, a 5-nitro-imidazole. IV. The role of the microflora.

Wolf FJ, Alvaro RF, Fiorentini K, Green M, Lu AY, Miwa GT, Wislocki PG, Koch RT, McLafferty MA, Goldman P.

Chem Biol Interact. 1983 Jul 1;45(1):7-14.

PMID:
6872101
44.

The opposing effects of N-hydroxyamphetamine and N-hydroxyphentermine on the H2O2 generated by hepatic cytochrome P-450.

Cho AK, Maynard MS, Matsumoto RM, Lindeke B, Paulsen U, Miwa GT.

Mol Pharmacol. 1982 Sep;22(2):465-70.

PMID:
7144739
45.

Drug residue formation from ronidazole, a 5-nitroimidazole. III. Studies on the mechanism of protein alkylation in vitro.

Miwa GT, West SB, Walsh JS, Wolf FJ, Lu AY.

Chem Biol Interact. 1982 Sep;41(3):297-312.

PMID:
6809347
46.

The metabolism of avermectins B1a, H2B1a, and H2B1b by liver microsomes.

Miwa GT, Walsh JS, VandenHeuvel WJ, Arison B, Sestokas E, Buhs R, Rosegay A, Avermitilis S, Lu AY, Walsh MA, Walker RW, Taub R, Jacob TA.

Drug Metab Dispos. 1982 May-Jun;10(3):268-74.

PMID:
6125361
47.

Studies on the stimulation of cytochrome P-450-dependent monooxygenase activity by dilauroylphosphatidylcholine.

Miwa GT, Lu AY.

Arch Biochem Biophys. 1981 Oct 1;211(1):454-8. No abstract available.

PMID:
6795999
48.
49.

Selective inactivation of cytochrome P-450 isozymes by suicide substrates.

Ortiz de Montellano PR, Mico BA, Mathews JM, Kunze KL, Miwa GT, Lu AY.

Arch Biochem Biophys. 1981 Sep;210(2):717-28. No abstract available.

PMID:
7305355
50.

Supplemental Content

Support Center